• Explore /
  • Poster
  • / A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.

A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.

Abstract Poster

Authors

null

Melissa Lynne Johnson

Sarah Cannon Research Institute, Nashville, TN

Melissa Lynne Johnson , Judy Sing-Zan Wang , Gerald Steven Falchook , Julie Charlton , Alexander MacDonald , Donald Strickland , Suzanne Fields Jones , Elizabeth J. Pease , Wolfram Brugger , Howard A. Burris III

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT02579226

Citation

J Clin Oncol 36, 2018 (suppl; abstr 2592)

DOI

10.1200/JCO.2018.36.15_suppl.2592

Abstract #

2592

Poster Bd #

418

Abstract Disclosures

Similar Posters

First Author: Melissa Lynne Johnson

First Author: Yan Song

First Author: Howard A. Burris III

First Author: Funda Meric-Bernstam